Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
29 juin 2023 16h01 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a quorum...
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
19 mai 2023 16h01 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about...
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
09 janv. 2023 08h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration...
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
14 nov. 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
08 nov. 2022 16h30 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s...
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
03 oct. 2022 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
15 août 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
08 août 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s...
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
13 juil. 2022 16h01 HE
|
Calithera Biosciences, Inc.
-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored...